Genomic Health, Inc. (NASDAQ:GHDX)‘s stock had its “hold” rating reaffirmed by equities researchers at Cowen and Company in a report released on Friday. They currently have a $34.00 target price on the medical research company’s stock. Cowen and Company’s price target suggests a potential upside of 7.26% from the company’s current price.

A number of other research analysts have also recently issued reports on GHDX. Jefferies Group LLC boosted their price objective on shares of Genomic Health from $29.00 to $33.00 and gave the company a “hold” rating in a report on Wednesday, May 10th. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Piper Jaffray Companies restated a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a report on Thursday, August 3rd. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, Canaccord Genuity decreased their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. Genomic Health presently has a consensus rating of “Hold” and an average price target of $32.00.

Genomic Health (GHDX) opened at 31.70 on Friday. Genomic Health has a 1-year low of $26.37 and a 1-year high of $33.97. The company has a 50-day moving average of $31.35 and a 200-day moving average of $31.43. The firm’s market cap is $1.10 billion.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. The firm had revenue of $85.50 million for the quarter, compared to analyst estimates of $86.08 million. Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.18) EPS. Analysts predict that Genomic Health will post ($0.01) earnings per share for the current year.

WARNING: “Cowen and Company Reiterates Hold Rating for Genomic Health, Inc. (GHDX)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/cowen-and-company-reiterates-hold-rating-for-genomic-health-inc-ghdx/1535374.html.

In other news, insider Phillip G. Febbo sold 3,174 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $33.57, for a total value of $106,551.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kimberly J. Popovits sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $30.22, for a total transaction of $151,100.00. The disclosure for this sale can be found here. Insiders sold 42,642 shares of company stock valued at $1,356,731 in the last quarter. Corporate insiders own 46.20% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GHDX. Dubuque Bank & Trust Co. boosted its position in Genomic Health by 8.4% in the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after buying an additional 379 shares during the period. SG Americas Securities LLC boosted its position in Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after buying an additional 1,679 shares during the period. Legal & General Group Plc boosted its position in Genomic Health by 48.7% in the first quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after buying an additional 2,038 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in Genomic Health during the first quarter valued at $218,000. Finally, Parametric Portfolio Associates LLC boosted its position in Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after buying an additional 441 shares during the period. Institutional investors own 88.91% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.